Amphastar Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 12/06/2023
Amphastar Pharmaceuticals Stock Forecast and Price Target
Amphastar Pharmaceuticals has an average price target of $66.00 recently offered by notable experts for 2023, which would represent a potential upside of approximately 13.3% from the last closing price in December, 2023 if reached. This potential increase is based on a high estimate of $71.00 and a low estimate of $63.00. If you are not interested in AMPH stock, you may be interested in its competitors.
13.30% Upside
Amphastar Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Price for Amphastar Pharmaceuticals has grown by 447.22%, going from $10.46 to $57.25. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $77.59 – an increase of 35.53%. Over the next eight years, experts anticipate that Fair Value growth for Amphastar Pharmaceuticals will be 152.45%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
16
|
$589.25 | Buy/Sell | $594.01 | 10.31% |
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
10
|
kr678.50 | Buy/Sell | kr696.07 | 14.22% |
| SUNPHARMA Stock Forecast | Sun Pharmaceutical Industries | Buy |
18
|
Rp1.24k | Buy/Sell | Rp845.39 | 3.20% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$9.83 | Buy/Sell | $12.04 | 9.36% |
| HALO Stock Forecast | Halozyme Therapeutics Inc | Outperform |
11
|
$39.97 | Buy/Sell | $51.90 | 25.09% |
Amphastar Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Revenue for Amphastar Pharmaceuticals has grown by 54.79%, going from $322.36M to $498.99M. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach $632.40M – an increase of 26.74%. Over the next eight years, experts anticipate that Revenue growth for Amphastar Pharmaceuticals will be 100.75%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£18.03 | Buy/Sell | £28.13 | 54.02% |
| PBH Stock Forecast | Prestige Consumer Healthcare | Buy |
16
|
$59.17 | Buy/Sell | $71.50 | 18.30% |
| BHC Stock Forecast | Bausch Health Companies | Outperform |
15
|
$7.17 | Buy/Sell | $34.09 | 11.58% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$26.78 | Buy/Sell | $41.00 | 54.97% |
| AMRX Stock Forecast | Amneal Pharmaceuticals | Outperform |
16
|
$4.55 | Buy/Sell | $6.30 | 31.87% |
| ANIP Stock Forecast | ANI Pharmaceuticals | Buy |
13
|
$48.72 | Buy/Sell | $71.00 | 43.68% |
Amphastar Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, Amphastar Pharmaceuticals's Free Cash Flow has grown, increasing from $200.00k to $61.72M – an increase of 30760.00%. 0 analysts predict Amphastar Pharmaceuticals's Free Cash Flow will decrease by 50.56% in the next year, reaching $30.51M. By 2030, professionals predict that Amphastar Pharmaceuticals's Free Cash Flow will decrease by 19.65%, to $49.59M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ZEAL Stock Forecast | Zealand Pharma A/S | Buy |
8
|
kr350.60 | Buy/Sell | kr241.83 | 11.52% |
| XERS Stock Forecast | Xeris Biopharma Holdings | Buy |
6
|
$1.92 | Buy/Sell | $0.00 | 134.38% |
| EBS Stock Forecast | Emergent BioSolutions | Hold |
16
|
$2.53 | Buy/Sell | $5.00 | 97.63% |
Amphastar Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030
In the last three years, Amphastar Pharmaceuticals's Net Income has increased by 86.74%, going from $48.94M to $91.39M. In the next year, analysts are expecting an increase in Net Income, predicting it will reach $170.10M – an increase of 86.13%. The Amphastar Pharmaceuticals forecast is for Net Income to reach $276.67M or grow by 202.74%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ASRT Stock Forecast | Assertio Holdings | Buy |
8
|
$1.10 | Buy/Sell | $6.75 | 263.64% |
| EGRX Stock Forecast | Eagle Pharmaceuticals Inc-DE | - |
14
|
$5.94 | Buy/Sell | $50.50 | -100.00% |
| OPNT Stock Forecast | Opiant Pharmaceuticals | Buy |
10
|
$20.89 | Buy/Sell | $43.00 | -100.00% |
Amphastar Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
Amphastar Pharmaceuticals's EBITDA has increased by 634.53% In the last three years, going from $18.07M to $132.73M. In the next year, analysts expect EBITDA to reach $225.75M – an increase of 70.08%. For the next eight years, the forecast is for EBITDA to grow by 204.22%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LCI Stock Forecast | Lannett Company | Hold |
10
|
$0.62 | Buy/Sell | $2.25 | 262.90% |
| ACOR Stock Forecast | Acorda Therapeutics Inc | - |
5
|
$12.49 | Buy/Sell | $5.00 | -100.00% |
| ADMP Stock Forecast | Adamis Pharmaceuticals | - |
8
|
$0.61 | Buy/Sell | $1.50 | -40.98% |
Amphastar Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Amphastar Pharmaceuticals's EBIT has grown, increasing from $-40.00k to $107.50M – a growth of 268850.00%. The next year looks promising for Amphastar Pharmaceuticals, with analysts predicting EBIT of $218.60M – an increase of 103.35%. Over the next eight years, experts anticipate that Amphastar Pharmaceuticals's EBIT will grow at a rate of 243.73%.
Amphastar Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, EPS for Amphastar Pharmaceuticals has grown by 447.22%, going from $0.36 to $1.97. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $2.67 – an increase of 35.53%. Over the next eight years, experts anticipate that EPS growth for Amphastar Pharmaceuticals will be 152.45%.
Site Navigation
.jpg)